CX 438

Drug Profile

CX 438

Latest Information Update: 18 Apr 1996

Price : $50

At a glance

  • Originator Cortex Pharmaceuticals
  • Class Antidementias; Neuroprotectants
  • Mechanism of Action Intercellular signalling peptide and protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 18 Apr 1996 New profile
  • 18 Apr 1996 Discontinued-Preclinical for Alzheimer's disease in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top